Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2003-02-20
2008-09-09
Maier, Leigh C. (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S454000, C514S455000, C514S733000, C514S738000
Reexamination Certificate
active
07423026
ABSTRACT:
The present invention is directed to novel complexes of cyclodextrin. In particular the invention is directed to a complex of a cyclodextrin selected from the group consisting of RM-β-cyclodextrin, DM-β-cyclodextrin and TM-β-cyclodextrin, and a cannabinoid selected from the classical cannabinoid-group consisting of cannabinol, tetrhydrocannabinol and cannabidiol.
REFERENCES:
patent: 4596795 (1986-06-01), Pitha
patent: 4599327 (1986-07-01), Nogradi et al.
patent: 5180716 (1993-01-01), Yaksh et al.
patent: 6383513 (2002-05-01), Watts et al.
patent: 7115586 (2006-10-01), Loftsson
patent: 2005/0153931 (2005-07-01), Jarho et al.
patent: WO-99/32107 (1999-07-01), None
Williamson, E. et al “Cannabinoids in clinical practice” Drugs (2000) vol. 60, No. 6, pp. 1303-1314.
Hancock, R. “Cationic antimicrobial peptides . . . ” Exp. Opin. Invest. Drugs (2000) vik 9, No. 8, pp. 1723-1729.
Szente, L. et al “Highly soluble cyclodextrin derivatives . . . ” Adv. Drug Deliv. Rev. (1999) vol. 36, pp. 17-28.
Hedges, A. “Industrial applications of cyclodextrins” Chem. Rev. (1998) vol. 98, pp. 2035-2044.
Kopecky, F. et al “Solubility study of nimodipine inclusion complexation . . . ” J. Incl. Phenom. Macr. Phen. (2001) vol. 39, pp. 215-217.
Worthington, M. et al “Phase solubility analysis in studying the interaction . . . ” J. Incl. Phenom. Macr. Phen. (1996) vol. 25, pp. 153-156.
Y. Shoyama et al., Journal of Natural Products, vol. 46, No. 5, 1983, p. 633-637.
Pekka Jarho et al., Life Sciences, vol. 63, No. 26, 1998, p. 381-384.
David W. Pate et al., Life Sciences, vol. 58, No. 21, 1996, p. 1849-1860.
Pekka Jarho et al., Life Sciences, vol. 58, No. 10, 1996, p. 181-185.
Loftsson et al,J. Pharm. Sci., 85(10):1017-1025 (1996).
Garrett et al,J. Pharm. Sci.(Abstract), 63(7):1056-1064 (2006).
Challa et al, “Cyclodextrins in Drug Delivery: An Updated Review”, Journal, AAPS-PharmSciTech, pp. 1-55, published Oct. 14, 2005.
Pitha et al,J. Pharm. Sci.(Abstract), 75(2):165-167 (2006).
Mannila et al,Eur. J. Pharm. Sci., (Article), pp. 1-7, published 2005.
Mannila et al,J. Pharm. Sci., 96(2):312-319 (2007).
Mannilla, Cyclodextrins in Intraoral Delivery of Δ9-tetrahydrocannabinol and Cannabidiol, Doctroal Dissertation, University of Kuopio (May 11, 2007).
Hazekamp et al,Eur. J. Pharm. Sci., 29:340-347 (2006).
Mannila et al,Life Sciences, 78:1911-1914 (2006).
Pitha et al,J. Pharm. Sci., 76(10):788-790 (1987).
Jarho Pekka
Järvinen Tomi
Mannila Janne
Birch & Stewart Kolasch & Birch, LLP
Maier Leigh C.
PediPharm Oy
LandOfFree
Methylated cyclodextrin complexes does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methylated cyclodextrin complexes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methylated cyclodextrin complexes will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3992539